Can This Beaten-Down AI Stock Bounce Back in 2026?

Recursion Pharmaceuticals (NASDAQ: RXRX) is a small-cap biotech with a mission. The company is looking to revolutionize the way we develop drugs through the use of artificial intelligence (AI). However, the company has had little success so far. Last year, Recursion Pharmaceuticals' shares fell significantly. Could the company bounce back this year?Image source: Getty Images.Recursion Pharmaceuticals uses an AI-powered operating system to test clinical compounds. The most promising get sent to clinical trials. The typical success rate for new compounds entering the clinic isn't high. Most never make it to the market. Recursion argues that its approach could boost the probability of success while also cutting the time and money typically spent on preclinical studies. If the biotech is right, it could transform the pharmaceutical industry.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool